SE0104330D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0104330D0
SE0104330D0 SE0104330A SE0104330A SE0104330D0 SE 0104330 D0 SE0104330 D0 SE 0104330D0 SE 0104330 A SE0104330 A SE 0104330A SE 0104330 A SE0104330 A SE 0104330A SE 0104330 D0 SE0104330 D0 SE 0104330D0
Authority
SE
Sweden
Prior art keywords
sub
sup
group
optionally substituted
alkyl
Prior art date
Application number
SE0104330A
Other languages
English (en)
Inventor
Kristina Berggren
Jonas Bostroem
Thomas Elebring
Peter Greasley
Emma Terricabras
Michael Wilstermann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104330A priority Critical patent/SE0104330D0/sv
Publication of SE0104330D0 publication Critical patent/SE0104330D0/sv
Priority to CNA028281535A priority patent/CN1620438A/zh
Priority to HU0402026A priority patent/HUP0402026A3/hu
Priority to PL02369731A priority patent/PL369731A1/xx
Priority to NZ533275A priority patent/NZ533275A/en
Priority to KR10-2004-7009589A priority patent/KR20040068286A/ko
Priority to PCT/GB2002/005742 priority patent/WO2003051851A1/en
Priority to CA002469786A priority patent/CA2469786A1/en
Priority to BR0214989-3A priority patent/BR0214989A/pt
Priority to AU2002352425A priority patent/AU2002352425A1/en
Priority to IL16237702A priority patent/IL162377A0/xx
Priority to US10/499,054 priority patent/US7342019B2/en
Priority to RU2004116916/04A priority patent/RU2004116916A/ru
Priority to JP2003552736A priority patent/JP2005517655A/ja
Priority to DE60218340T priority patent/DE60218340T2/de
Priority to EP02788143A priority patent/EP1458690B1/en
Priority to AT02788143T priority patent/ATE354570T1/de
Priority to ES02788143T priority patent/ES2280599T3/es
Priority to MXPA04005990A priority patent/MXPA04005990A/es
Priority to TW091136671A priority patent/TW200410694A/zh
Priority to ARP020105001A priority patent/AR038044A1/es
Priority to IS7314A priority patent/IS7314A/is
Priority to ZA200404805A priority patent/ZA200404805B/en
Priority to CO04065292A priority patent/CO5590917A2/es
Priority to NO20043022A priority patent/NO20043022L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0104330A 2001-12-19 2001-12-19 Therapeutic agents SE0104330D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0104330A SE0104330D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
MXPA04005990A MXPA04005990A (es) 2001-12-19 2002-12-18 Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1.
IL16237702A IL162377A0 (en) 2001-12-19 2002-12-18 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
RU2004116916/04A RU2004116916A (ru) 2001-12-19 2002-12-18 Производные 5,6-биарил-пиразин-2-амида в качестве антагонистов cb1
PL02369731A PL369731A1 (en) 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
NZ533275A NZ533275A (en) 2001-12-19 2002-12-18 5, 6-Diaryl-pyrazine-2-amide derivatives as CB1 antagonists
KR10-2004-7009589A KR20040068286A (ko) 2001-12-19 2002-12-18 Ｃｂ１ 길항물질로서의 5,6-디아릴-피라진-2-아미드 유도체
PCT/GB2002/005742 WO2003051851A1 (en) 2001-12-19 2002-12-18 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
CA002469786A CA2469786A1 (en) 2001-12-19 2002-12-18 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
BR0214989-3A BR0214989A (pt) 2001-12-19 2002-12-18 Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto
AU2002352425A AU2002352425A1 (en) 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists
CNA028281535A CN1620438A (zh) 2001-12-19 2002-12-18 用作cbi拮抗剂的5,6－二芳基－吡嗪－2－酰胺衍生物
US10/499,054 US7342019B2 (en) 2001-12-19 2002-12-18 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists
HU0402026A HUP0402026A3 (en) 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them
JP2003552736A JP2005517655A (ja) 2001-12-19 2002-12-18 Ｃｂ１アンタゴニストとしての５，６−ジアリール−ピラジン−２−アミド誘導体
DE60218340T DE60218340T2 (de) 2001-12-19 2002-12-18 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
EP02788143A EP1458690B1 (en) 2001-12-19 2002-12-18 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
AT02788143T ATE354570T1 (de) 2001-12-19 2002-12-18 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
ES02788143T ES2280599T3 (es) 2001-12-19 2002-12-18 Derivados de 5,6-diaril-pirazin-2-amida como antagonistas de cb1.
ARP020105001A AR038044A1 (es) 2001-12-19 2002-12-19 Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
TW091136671A TW200410694A (en) 2001-12-19 2002-12-19 Therapeutic agents
IS7314A IS7314A (is) 2001-12-19 2004-06-16 5,6-díarýl-pýrasín-2-amíðafleiður sem cb1 mótlyf
ZA200404805A ZA200404805B (en) 2001-12-19 2004-06-17 5,6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists.
CO04065292A CO5590917A2 (es) 2001-12-19 2004-07-09 Derivados de 5,6-diaril-pirazina-2-amida como antagonistas cb1
NO20043022A NO20043022L (no) 2001-12-19 2004-07-15 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104330A SE0104330D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0104330D0 true SE0104330D0 (sv) 2001-12-19

Family

ID=20286429

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104330A SE0104330D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Country Status (25)

Country Link
US (1) US7342019B2 (sv)
EP (1) EP1458690B1 (sv)
JP (1) JP2005517655A (sv)
KR (1) KR20040068286A (sv)
CN (1) CN1620438A (sv)
AR (1) AR038044A1 (sv)
AT (1) ATE354570T1 (sv)
AU (1) AU2002352425A1 (sv)
BR (1) BR0214989A (sv)
CA (1) CA2469786A1 (sv)
CO (1) CO5590917A2 (sv)
DE (1) DE60218340T2 (sv)
ES (1) ES2280599T3 (sv)
HU (1) HUP0402026A3 (sv)
IL (1) IL162377A0 (sv)
IS (1) IS7314A (sv)
MX (1) MXPA04005990A (sv)
NO (1) NO20043022L (sv)
NZ (1) NZ533275A (sv)
PL (1) PL369731A1 (sv)
RU (1) RU2004116916A (sv)
SE (1) SE0104330D0 (sv)
TW (1) TW200410694A (sv)
WO (1) WO2003051851A1 (sv)
ZA (1) ZA200404805B (sv)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CA2527033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314049D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US20050014786A1 (en) 2003-07-11 2005-01-20 Chongqing Sun Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
CA2543197A1 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
TW200528102A (en) * 2003-10-24 2005-09-01 Solvay Pharm Gmbh Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
GB0327331D0 (en) * 2003-11-25 2003-12-31 Astrazeneca Ab Therapeutic agents
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
BRPI0517434A (pt) 2004-10-25 2008-10-07 Solvay Pharm Gmbh composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados
DE602006007563D1 (de) 2005-04-06 2009-08-13 Hoffmann La Roche Agonisten
AU2006236387A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
WO2008040651A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
PT2114933E (pt) 2007-01-04 2011-12-20 Prosidion Ltd Agonistas do gpcr de piperidina
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
US20100048625A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives
BR112023002139A2 (pt) 2020-08-06 2023-04-18 Chdi Foundation Inc Compostos de heterobiarila e agentes de imageamento para proteína huntingtina
WO2024159286A1 (pt) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Compostos fenólicos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
WO2024159284A1 (pt) * 2023-01-30 2024-08-08 Eurofarma Laboratórios S.A. Hidrazidas bloqueadoras de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH458361A (de) 1965-01-15 1968-06-30 Eprova Ag Verfahren zur Herstellung von Pyrazincarbonsäuren
JPS5322529A (en) * 1976-08-13 1978-03-02 Nippon Soda Co Ltd Dihydropyrazine derivative and its preparation
WO1989004308A1 (en) 1987-11-12 1989-05-18 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
WO1992002513A1 (en) * 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.

Also Published As

Publication number Publication date
EP1458690A1 (en) 2004-09-22
HUP0402026A2 (hu) 2005-02-28
TW200410694A (en) 2004-07-01
MXPA04005990A (es) 2004-09-27
BR0214989A (pt) 2004-12-14
CN1620438A (zh) 2005-05-25
US20050032808A1 (en) 2005-02-10
HUP0402026A3 (en) 2005-08-29
ES2280599T3 (es) 2007-09-16
EP1458690B1 (en) 2007-02-21
ZA200404805B (en) 2005-08-15
US7342019B2 (en) 2008-03-11
IL162377A0 (en) 2005-11-20
JP2005517655A (ja) 2005-06-16
PL369731A1 (en) 2005-05-02
CA2469786A1 (en) 2003-06-26
RU2004116916A (ru) 2005-11-10
AR038044A1 (es) 2004-12-22
CO5590917A2 (es) 2005-12-30
NZ533275A (en) 2006-02-24
KR20040068286A (ko) 2004-07-30
NO20043022L (no) 2004-07-15
ATE354570T1 (de) 2007-03-15
WO2003051851A1 (en) 2003-06-26
IS7314A (is) 2004-06-16
AU2002352425A1 (en) 2003-06-30
DE60218340T2 (de) 2007-11-29
DE60218340D1 (de) 2007-04-05

Similar Documents

Publication Publication Date Title
SE0104330D0 (sv) Therapeutic agents
TW200503692A (en) Therapeutic agents
TW200507839A (en) Therapeutic agents
HUP0402150A2 (hu) A CB1 jelzésű kannabinoid receptorra nézve agonista, parciális agonista vagy antagonista hatású 1H-imidazol-származékok, eljárás az előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
WO2002089782A3 (en) Dioxanes and uses thereof
PT842923E (pt) Derivados do pirrolo e composicoes medicinais
AU8799201A (en) Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
PL353646A1 (en) Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
SI1210320T1 (en) Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
IL148875A0 (en) Sulfonyl hydrazide derivatives, their preparation and pharmaceutical compositions containing them
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
CA2345069A1 (en) 2-phenylpyran-4-one derivatives
ATE185806T1 (de) Oxopyridylchinoxalin derivate
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
NO996284L (no) Nye imidazolinforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
ATE397609T1 (de) Corticotropinfreisetzungsfaktor antagonisten
HK1096670A1 (en) Pyrrolo-pyrazine derivatives useful as cb1-modulators
ATE409698T1 (de) 1,2,4-triazolderivat, verfahren zu dessen herstellung, und dieses enthaltende pharmazeutische zusammensetzung
AP2002002707A0 (en) 4, 5-Dihydro-Thiazo-2-Ylamine Derivatives and their Use as NO-Synthase Inhibitors.